These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9562949)

  • 1. [Factors that determine intensity of response to treatment with tiludronate in Paget's disease].
    Morales Piga A; Abraira Santos V; Rey Rey JS; de Abajo Iglesias F
    Med Clin (Barc); 1998 Feb; 110(7):254-8. PubMed ID: 9562949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone.
    Reginster JY; Treves R; Renier JC; Amor B; Sany J; Ethgen D; Picot C; Franchimont P
    J Bone Miner Res; 1994 May; 9(5):615-9. PubMed ID: 8053389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy and bioequivalence of two oral formulations of tiludronate in the treatment of Paget's disease of bone.
    Morales-Piga A; Del Pino J; Rapado A; Diaz-Curiel M; Pallares M; Gonzalez-Macias J
    Clin Ther; 1997; 19(5):963-74. PubMed ID: 9385484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
    Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
    Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paget's disease of bone: experience from a centre in southern India.
    Anjali ; Thomas N; Rajaratnam S; Shanthly N; Oommen R; Seshadri MS
    J Assoc Physicians India; 2006 Jul; 54():525-9. PubMed ID: 17089899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tiludronate therapy for Paget's disease of bone.
    McClung MR; Tou CK; Goldstein NH; Picot C
    Bone; 1995 Nov; 17(5 Suppl):493S-496S. PubMed ID: 8573425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone.
    Chakravarty K; Merry P; Scott DG
    J Rheumatol; 1994 Nov; 21(11):2118-21. PubMed ID: 7869320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paget's disease of bone treated in five days with AHPrBP (APD) per Os.
    Thiébaud D; Jaeger P; Burckhardt P
    J Bone Miner Res; 1987 Feb; 2(1):45-52. PubMed ID: 3455156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study.
    Reginster JY; Colson F; Morlock G; Combe B; Ethgen D; Geusens P
    Arthritis Rheum; 1992 Aug; 35(8):967-74. PubMed ID: 1642662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pamidronate infusions for the treatment of Paget's disease of bone.
    Mazieres B; Ahmed I; Moulinier L; Bon E; Cantagrel A; Laroche M
    Rev Rhum Engl Ed; 1996 Jan; 63(1):36-43. PubMed ID: 9064108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (Chloro-4 phenyl) thiomethylene biphosphonate in Paget's bone disease.
    Reginster JY; Deroisy R; Lecart MP; Franchimont P
    Acta Belg Med Phys; 1989; 12(2):47-52. PubMed ID: 2603591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The treatment of Paget's disease of bone with second-generation bisphosphonates via intravenous infusion].
    Arboleya L; Sánchez J; Iglesias G; Arranz JL
    Rev Clin Esp; 1993 Dec; 193(9):467-71. PubMed ID: 8108576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate resistance in Paget's disease of bone.
    Joshua F; Epstein M; Major G
    Arthritis Rheum; 2003 Aug; 48(8):2321-3. PubMed ID: 12905487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone.
    Roux C; Gennari C; Farrerons J; Devogelaer JP; Mulder H; Kruse HP; Picot C; Titeux L; Reginster JY; Dougados M
    Arthritis Rheum; 1995 Jun; 38(6):851-8. PubMed ID: 7779130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained biochemical effects of short treatment of Paget's disease of bone with dichloromethylene diphosphonate.
    Chapuy MC; Charhon SA; Meunier PJ
    Metab Bone Dis Relat Res; 1983; 4(6):325-8. PubMed ID: 6229683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
    Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of surgical menopause and Paget's disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: evolution after antiresorptive therapy.
    Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Echevarría M; Ros I; Ballesta AM; Muñoz-Gómez J
    J Bone Miner Metab; 2002; 20(2):116-20. PubMed ID: 11862534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.